John Wallace
Voorzitter bij Antibe Holdings, Inc.
Vermogen: 279 012 $ op 30-04-2024
Profiel
John Lawrence Wallace is the founder of Antibe Therapeutics, Inc. which was founded in 2009.
He held the title of Director & Chief Scientific Officer from 2013 to 2022.
Dr. Wallace is also the founder of Nicox SA. Currently, he is the Chairman & Chief Scientific Officer at Antibe Holdings, Inc., a Director at Medicago, Inc., and a Professor at both McMaster University and Cumming School of Medicine.
Previously, he was the Founding Director of Farncombe Family Digestive Health Research Institute from 2009 to 2012 and served as President of the Canadian Association of Gastroenterology.
Dr. Wallace received his undergraduate and graduate degrees from Queen's University, his doctorate from the University of Toronto, and his MBA from the University of Birmingham.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 13-12-2022 | 1 965 705 ( 3.73% ) | 279 012 $ | 30-04-2024 |
Actieve functies van John Wallace
| Bedrijven | Functie | Begin |
|---|---|---|
Antibe Holdings, Inc.
 Antibe Holdings, Inc. Financial ConglomeratesFinance Part of Antibe Therapeutics, Inc., Antibe Holdings, Inc. is a Canadian company that functions as an investment holding company. The company is based in Toronto, Canada. Antibe Holdings was acquired by Antibe Therapeutics, Inc. on June 03, 2021 for $19.02 million. Daniel Legault has been the CEO of the company since 2005. | Voorzitter | - |
| McMaster University | Corporate Officer/Principal | - |
Medicago, Inc.
 Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | Directeur/Bestuurslid | - |
| Cumming School of Medicine | Corporate Officer/Principal | - |
Eerdere bekende functies van John Wallace
| Bedrijven | Functie | Einde |
|---|---|---|
| Farncombe Family Digestive Health Research Institute | Directeur/Bestuurslid | 01-01-2012 |
| NICOX SA | Oprichter | - |
Canadian Association of Gastroenterology
 Canadian Association of Gastroenterology Miscellaneous Commercial ServicesCommercial Services Canadian Association of Gastroenterology promotes the study of the digestive tract in health and disease. It supports the development and maintenance of formal educational research component within Gastroenterology in Canada. The company was founded in 1962 and is headquartered in Oakville, Canada. | President | - |
| ANTIBE THERAPEUTICS INC. | Oprichter | - |
Opleiding van John Wallace
| University of Toronto | Doctorate Degree |
| Queen's University | Graduate Degree |
| University of Birmingham | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ANTIBE THERAPEUTICS INC. | Health Technology |
| NICOX SA | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Antibe Holdings, Inc.
Antibe Holdings, Inc. Financial ConglomeratesFinance Part of Antibe Therapeutics, Inc., Antibe Holdings, Inc. is a Canadian company that functions as an investment holding company. The company is based in Toronto, Canada. Antibe Holdings was acquired by Antibe Therapeutics, Inc. on June 03, 2021 for $19.02 million. Daniel Legault has been the CEO of the company since 2005. | Finance |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | Health Technology |
| Farncombe Family Digestive Health Research Institute | |
Canadian Association of Gastroenterology
Canadian Association of Gastroenterology Miscellaneous Commercial ServicesCommercial Services Canadian Association of Gastroenterology promotes the study of the digestive tract in health and disease. It supports the development and maintenance of formal educational research component within Gastroenterology in Canada. The company was founded in 1962 and is headquartered in Oakville, Canada. | Commercial Services |
